. home.aspx



Merck/Pfizer’s Bavencio flunks second ovarian cancer trial

December 24, 2018 / Phil Taylor

Merck KGaA and Pfizer PD-L1 inhibitor Bavencio has missed the mark in its second ovarian cancer trial in a month, this time failing in previously-untreated patients. Results from a planned interim analysis of the phase III JAVELIN Ovarian 100 trial showed that Bavencio (avelumab) was unable to improve progression-free survival (PFS) compared to control groups when used as a maintenance therapy. The failure comes just a few weeks after Merck and Pfizer conceded defeat in another phase III trial of Bavencio in ovarian cancer. The JAVELIN Ovarian 200 trial involved patients with platinum-resistant or platinum-refractory ovarian cancer. The latest study compared initial chemotherapy followed by Bavencio maintenance to chemotherapy plus Bavencio followed by maintenance with the drug, and a control group of chemotherapy followed by observation. All those enrolled had advanced (stage III to IV) ovarian cancer and were being treated for the first time.